Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported financial results for the fiscal year ended September 30, 2008. At September 30, 2008, Pharmasset held $63.6 million in cash and cash equivalents and short term investments.

Pipeline Update and 2008 Highlights

Clevudine

During 2008, new data from multiple investigator sponsored studies supported the potential of clevudine to treat hepatitis B (HBV), including its use in lamivudine resistant patients. Data from one study suggested that clevudine is as effective as entecavir (Baraclude(R)) and that it can be effectively used in combination with adefovir (Hepsera(R)). Management believes the unique attributes of clevudine will help to differentiate it in the marketplace, including its potential to achieve a sustained virological response (SVR) in patients after a defined treatment period.

In July of 2008, the French National Agency for Research on AIDS and Viral Hepatitis initiated a study to compare treatment with clevudine or tenofovir with a combination of the two. In this study patients will be treated for two years, followed by a determination of the SVR rates.

Pharmasset is currently enrolling two registration trials worldwide (studies 305 and 306) and as a result of unforeseen regulatory delays that impacted the start up in certain countries, the company expects to complete enrollment at the end of the first calendar quarter of 2009.

R7128

During 2008, Pharmasset made significant progress with our hepatitis C virus (HCV) programs. R7128, our lead HCV nucleoside inhibitor, completed 28 day clinical studies in both treatment n
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... will participate in the upcoming 27 th Annual ... Dana Point, CA.  Dr. Michael ... Oramed, will present a corporate overview on March 10, ...
(Date:3/4/2015)... Mallinckrodt plc (NYSE: MNK ), a ... Global Healthcare Conference at the Loews Miami Hotel in ... 11, 2015. Mark Trudeau, President and Chief Executive Officer of ... to begin at 10:45 a.m. Eastern. Individuals ... webcast information on Mallinckrodt,s Investor Relations website ...
(Date:3/4/2015)... NEWARK, N.J. , March 4, 2015 /PRNewswire/ ... biopharmaceutical company developing innovative medicines for serious women,s ... 1 clinical program demonstrating that its lead product ... had predictable pharmacokinetics (PK), and that contraceptive efficacy ... by SYM-1219 administration. These results will ...
Breaking Medicine Technology:Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... MedShape Solutions, Inc., the industry leader in innovative ... developed new, larger sizes of its ExoShape CL, ... simplifies and improves soft tissue graft fixation during ... comes after MedShape received the U.S. Food and ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced that ... the ongoing Phase Ia trial to test the safety of ... testing the drug in healthy volunteers for safety and tolerability. ... that stimulates new neuron growth in the hippocampus, an area ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:3/4/2015)... DC (PRWEB) March 04, 2015 ... additional discussion leaders for its upcoming fifth annual ... in Paris, France. The event this year will ... more than 20 of the field’s leading companies ... bring together top executives and clinical researchers from ...
(Date:3/4/2015)... March 04, 2015 Jeannie Mai, TV personality, ... Real” graces the cover of the print publication. Mai embraces ... choose organic when shopping for clothes and personal care products. ... up about her commitment to an organic diet. She mentions, ... not only in gymnastics, but also now as I’m a ...
(Date:3/4/2015)... 2015 i2i Systems Population Health ... Chase Brexton Health Care, a 35-year-old Maryland-based community ... Brexton provides comprehensive primary care, behavioral health and ... seven clinics in the greater Baltimore area of ... records, the organization has always focused on providing ...
(Date:3/4/2015)... A new dieting routine, called the feast ... extending life. Studies conducted by the University ... can help extend life by increasing anti-oxidant production. While ... benefits, many suffering from obesity are already experiencing life ... As an alternative to the new Feast and Famine ...
(Date:3/4/2015)... Nitrosigine®, a patented complex of bonded arginine ... products, is hosting the Nitrosigine Pump Challenge at the ... at The Arnold Sports Festival in Columbus, Ohio. The ... 8, 2015. , Nitrosigine is a patented ingredient ... notification status; now affirmed as GRAS.^ It has been ...
Breaking Medicine News(10 mins):Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3
... conference,focusing on the future of healthcare will convene ... Summit will present an opportunity for leaders from,around ... and future seismic,"tremors" in the healthcare industry in ... make the industry virtually unrecognizable in,the coming years., ...
... Corporation (Nasdaq: HLTH ) and its approximately 83% owned ... they will release,their respective financial results for the three months ... May 6, 2008. The Companies,will host a conference call at ... Investors can access the call via webcast at http://www.hlth.com ...
... Medicine Led by Simmons School for Health,Studies, BOSTON, ... (Dietary Approaches to Stop Hypertension), which is high in,fruits ... risk of coronary heart disease and stroke, according to ... Internal Medicine., The study indicates for the first ...
... amount had almost half the risk of needing to start ... with naturally high levels of the antioxidant urate in their ... than those with lower levels do, a new report says. ... Archives of Neurology , support early laboratory studies about ...
... DASH diet cuts cardiovascular risk, studies find , , MONDAY, ... additional benefits of widely used measures aimed at preventing ... the DASH diet for blood pressure control lowers the ... , The statin study wasn,t intended to measure the ...
... Americas Baby Boomer generation, arthritis is a growing ... common joint disease currently afflicts over 20 million ... aggravate matters, arthritis is also prevalent among the ... adult population. Fortunately, treating the pain and disability ...
Cached Medicine News:Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Risk of Women's Heart Attack or Stroke Appears to Be Lowered by 'DASH' Diet 2Health News:Elevated Urate Levels May Slow Parkinson's in Men 2Health News:New Benefits From Old Heart Measures 2Health News:New Benefits From Old Heart Measures 3Health News:Study shows increase of hip and knee replacements in the US 2Health News:Study shows increase of hip and knee replacements in the US 3
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
... Osteocalcin, also known as bone Gla protein, ... which is a major component of the ... by osteoblasts in bone, with a small ... hypertrophic chondrocytes [1]. During bone formation, newly ...
... Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) is ... which specifically binds and modulates the bioactivity ... of IGFBP-1 has not been completely defined, ... that IGFBP-1 may be involved in glucose ...
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
Medicine Products: